A citation-based method for searching scientific literature

Bhavya Voleti, Andrea Navarria, Rong-Jian Liu, Mounira Banasr, Nanxin Li, Rose Terwilliger, Gerard Sanacora, Tore Eid, George Aghajanian, Ronald S Duman. Biol Psychiatry 2013
Times Cited: 185



Carlos A Zarate, Jaskaran B Singh, Paul J Carlson, Nancy E Brutsche, Rezvan Ameli, David A Luckenbaugh, Dennis S Charney, Husseini K Manji. Arch Gen Psychiatry 2006
Times Cited: 2196




List of shared articles



Times cited


Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.
Chad R Johnson, Brian D Kangas, Emily M Jutkiewicz, Jack Bergman, Andrew Coop. Biomedicines 2022
2


Inhibition of GABA interneurons in the mPFC is sufficient and necessary for rapid antidepressant responses.
Manoela V Fogaça, Min Wu, Chan Li, Xiao-Yuan Li, Marina R Picciotto, Ronald S Duman. Mol Psychiatry 2021
9

Antidepressant Actions of Ketamine: Potential Role of L-Type Calcium Channels.
Bonnie Robinson, Qiang Gu, Jyotshna Kanungo. Chem Res Toxicol 2021
1

Neurobiology of the Rapid-Acting Antidepressant Effects of Ketamine: Impact and Opportunities.
Ryota Shinohara, George K Aghajanian, Chadi G Abdallah. Biol Psychiatry 2021
9

A low-dose combination of ketamine and guanosine counteracts corticosterone-induced depressive-like behavior and hippocampal synaptic impairments via mTORC1 signaling.
Anderson Camargo, Ana Paula Dalmagro, Ingrid A V Wolin, Aline Siteneski, Ana Lúcia B Zeni, Ana Lúcia S Rodrigues. Prog Neuropsychopharmacol Biol Psychiatry 2021
6

MeCP2 for sustained antidepressant effects.
Shane Johnson, Conor Liston. Nat Neurosci 2021
3

Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation.
Ji-Woon Kim, Anita E Autry, Elisa S Na, Megumi Adachi, Carl Björkholm, Ege T Kavalali, Lisa M Monteggia. Nat Neurosci 2021
19

Resolvins as potential candidates for the treatment of major depressive disorder.
Satoshi Deyama, Masabumi Minami, Katsuyuki Kaneda. J Pharmacol Sci 2021
4



Ketamine: The final frontier or another depressing end?
Omar K Sial, Eric M Parise, Lyonna F Parise, Tamara Gnecco, Carlos A Bolaños-Guzmán. Behav Brain Res 2020
14



Medial PFC AMPA receptor and BDNF signaling are required for the rapid and sustained antidepressant-like effects of 5-HT1A receptor stimulation.
Kenichi Fukumoto, Manoela V Fogaça, Rong-Jian Liu, Catharine H Duman, Xiao-Yuan Li, Shigeyuki Chaki, Ronald S Duman. Neuropsychopharmacology 2020
16

Guanosine potentiates the antidepressant-like effect of subthreshold doses of ketamine: Possible role of pro-synaptogenic signaling pathway.
Anderson Camargo, Ana Paula Dalmagro, Ana Lúcia B Zeni, Ana Lúcia S Rodrigues. J Affect Disord 2020
11


Involvement of muscarinic receptor mechanisms in antidepressant drug action.
Jeffrey M Witkin, Jodi L Smith, Lalit K Golani, Emily A Brooks, Anna E Martin. Adv Pharmacol 2020
4

The antidepressant efficacy of the muscarinic antagonist scopolamine: Past findings and future directions.
Wayne C Drevets, Anindya Bhattacharya, Maura L Furey. Adv Pharmacol 2020
6

The effects of intramuscular administration of scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Jingjing Zhou, Jian Yang, Xuequan Zhu, Tarek Zghoul, Lei Feng, Runsen Chen, Gang Wang. Ther Adv Psychopharmacol 2020
1

Rapid acting antidepressants in the mTOR pathway: Current evidence.
Athira K V, Arathy S Mohan, Sumana Chakravarty. Brain Res Bull 2020
9

Role of the medial prefrontal cortex in the effects of rapid acting antidepressants on decision-making biases in rodents.
C A Hales, J M Bartlett, R Arban, B Hengerer, E S J Robinson. Neuropsychopharmacology 2020
4

mTORC1-dependent signaling pathway underlies the rapid effect of creatine and ketamine in the novelty-suppressed feeding test.
Francis L Pazini, Julia M Rosa, Anderson Camargo, Daiane B Fraga, Morgana Moretti, Aline Siteneski, Ana Lúcia S Rodrigues. Chem Biol Interact 2020
15

Transient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth.
Calvin Ly, Alexandra C Greb, Maxemiliano V Vargas, Whitney C Duim, Ana Cristina G Grodzki, Pamela J Lein, David E Olson. ACS Pharmacol Transl Sci 2020
17

Sex differences in antidepressant efficacy.
Tara A LeGates, Mark D Kvarta, Scott M Thompson. Neuropsychopharmacology 2019
62

Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
Lawrence Park, Maura Furey, Allison C Nugent, Cristan Farmer, Jessica Ellis, Joanna Szczepanik, Marc S Lener, Carlos A Zarate. Int J Neuropsychopharmacol 2019
14

Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.
Todd D Gould, Carlos A Zarate, Scott M Thompson. Annu Rev Pharmacol Toxicol 2019
61

Sex Differences in the Temporal Neuromolecular and Synaptogenic Effects of the Rapid-acting Antidepressant Drug Ketamine in the Mouse Brain.
Connor Thelen, Emily Flaherty, Joseph Saurine, Jonathon Sens, Sara Mohamed, Pothitos M Pitychoutis. Neuroscience 2019
24

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine.
Kenichi Fukumoto, Manoela V Fogaça, Rong-Jian Liu, Catharine Duman, Taro Kato, Xiao-Yuan Li, Ronald S Duman. Proc Natl Acad Sci U S A 2019
87

Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects.
Brendan D Hare, Ryota Shinohara, Rong Jian Liu, Santosh Pothula, Ralph J DiLeone, Ronald S Duman. Nat Commun 2019
92

Neurotrophic and Antidepressant Actions of Brain-Derived Neurotrophic Factor Require Vascular Endothelial Growth Factor.
Satoshi Deyama, Eunyoung Bang, Taro Kato, Xiao-Yuan Li, Ronald S Duman. Biol Psychiatry 2019
45

Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines.
Mervin Chávez-Castillo, Victoria Núñez, Manuel Nava, Ángel Ortega, Milagros Rojas, Valmore Bermúdez, Joselyn Rojas-Quintero. Adv Pharmacol Sci 2019
19



Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function.
Ronald S Duman, Ryota Shinohara, Manoela V Fogaça, Brendan Hare. Mol Psychiatry 2019
68

Augmentation effect of ketamine by guanosine in the novelty-suppressed feeding test is dependent on mTOR signaling pathway.
Anderson Camargo, Francis L Pazini, Julia M Rosa, Ingrid A V Wolin, Morgana Moretti, Priscila B Rosa, Vivian B Neis, Ana Lúcia S Rodrigues. J Psychiatr Res 2019
26

Rapid-acting antidepressants.
Jeffrey M Witkin, Anna E Martin, Lalit K Golani, Nina Z Xu, Jodi L Smith. Adv Pharmacol 2019
27


Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23.
Satoshi Deyama, Kento Shimoda, Hiroe Suzuki, Yuka Ishikawa, Kohei Ishimura, Hayato Fukuda, Natsuko Hitora-Imamura, Soichiro Ide, Masamichi Satoh, Katsuyuki Kaneda,[...]. Psychopharmacology (Berl) 2018
36

Convergent Mechanisms Underlying Rapid Antidepressant Action.
Panos Zanos, Scott M Thompson, Ronald S Duman, Carlos A Zarate, Todd D Gould. CNS Drugs 2018
93


The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?
Chadi G Abdallah, Gerard Sanacora, Ronald S Duman, John H Krystal. Pharmacol Ther 2018
99

Psychedelics Promote Structural and Functional Neural Plasticity.
Calvin Ly, Alexandra C Greb, Lindsay P Cameron, Jonathan M Wong, Eden V Barragan, Paige C Wilson, Kyle F Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R Paddy,[...]. Cell Rep 2018
256